A mid-cap pharma company seeking to establish a biologics pipeline through partnership with a monoclonal antibody development boutique needed an assessment of target opportunities, soundness of third-party contracts, and underlying IP position and risks.
We assessed the likelihood that the application of a suite of novel antibody discovery tools would lead to new patentable drugs against known and novel targets.
We also reviewed the commercial aspects of third-party contracts against minimum acceptable terms that would protect the interests of our client.
In addition, a number of potential drug development programs were assessed, identifying the key target, clinical and market risks. We modeled certain scenarios (e.g. marketed vs. development stage bio-better) to allow our client to understand the overall value of this partnership.Back